TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.
|Oppenheimer 15th Annual Israeli Investor Conference|
|Date:||Sunday, May 11, 2014|
|Time:||7:10am Eastern/1:10pm GMT +2|
|Location:||David Intercontinental Hotel in Tel-Aviv|
|MIXiii/BioMed Israel Innovation Conference|
|Date:||Wednesday, May 21, 2014|
|Panel Title:||"Riding the IPO Wave"|
|Time:||9am Eastern/3pm GMT +2|
|Company Presentation||11am Eastern/5pm GMT +2|
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 firstname.lastname@example.org
|Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders|
|Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014|
|Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting|
|Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders|
|Regal Beloit Corporation To Present At The Oppenheimer 9th Annual Industrials Conference|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.